Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia

Br J Haematol. 2020 Jun;189(5):e200-e204. doi: 10.1111/bjh.16622. Epub 2020 Apr 3.

Authors

Xiaoxia Wu^{1

2}, Jian Zhang^{1

2}, Qiwei Chen^{1

2}, Lili Zhou^{1

2}, Mengyun Li^{1

2}, Huiying Qiu^{1

2}, Aining Sun^{1

2}, Depei Wu^{1

2}

Affiliations

¹ Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Suzhou, China.
² Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

PMID: 32242923
DOI: 10.1111/bjh.16622

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azacitidine / administration & dosage
Azacitidine / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Combined Modality Therapy
Drug Resistance, Neoplasm
Female
Hematologic Diseases / chemically induced
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Biphenotypic, Acute / drug therapy
Leukemia, Biphenotypic, Acute / genetics
Leukemia, Biphenotypic, Acute / therapy*
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Mutation
Nausea / chemically induced
Oncogene Proteins, Fusion / genetics
Sulfonamides / administration & dosage
Sulfonamides / adverse effects
Transplantation, Haploidentical*
Treatment Outcome
Vomiting / chemically induced

Substances

Bridged Bicyclo Compounds, Heterocyclic
Oncogene Proteins, Fusion
Sulfonamides
Azacitidine
venetoclax

Grants and funding